$109 Million is the total value of Knoll Capital Management, LLC's 23 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 4.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHVN | Buy | Biohaven Pharmactl Hldg Co L | $35,775,000 | +9.0% | 857,494 | +14.4% | 32.74% | +21.8% |
| CRBP | Corbus Pharmaceuticals HLDGS | $24,281,000 | -29.7% | 4,985,870 | 0.0% | 22.22% | -21.4% | |
| BX | Blackstone Group LP | $7,473,000 | +10.0% | 153,000 | 0.0% | 6.84% | +22.9% | |
| ABEO | Abeona Therapeutics Inc | $5,333,000 | -52.7% | 2,359,767 | 0.0% | 4.88% | -47.1% | |
| APLT | Applied Therapeutics Inc | $5,133,000 | +33.4% | 467,071 | 0.0% | 4.70% | +49.1% | |
| KRYS | Sell | Krystal Biotech Inc | $4,174,000 | -29.5% | 120,212 | -18.3% | 3.82% | -21.2% |
| MO | Altria Group Inc | $3,681,000 | -13.6% | 90,000 | 0.0% | 3.37% | -3.4% | |
| EIGR | Eiger Biopharmaceuticals Inc | $3,590,000 | -3.3% | 350,238 | 0.0% | 3.29% | +8.1% | |
| KBA | Kraneshares TRbosera msci ch | $2,870,000 | -3.4% | 96,000 | 0.0% | 2.63% | +8.0% | |
| ALDX | Buy | Aldeyra Therapeutics Inc | $2,801,000 | -11.8% | 531,568 | +0.4% | 2.56% | -1.4% |
| LUMN | New | Centurylink Inc | $2,746,000 | – | 220,000 | +100.0% | 2.51% | – |
| AVXL | Anavex Life Sciences Corp | $2,288,000 | -6.3% | 724,205 | 0.0% | 2.09% | +4.8% | |
| DD | Dupont de Nemours Inc | $2,139,000 | -5.0% | 30,000 | 0.0% | 1.96% | +6.2% | |
| DOW | Dow Inc | $1,430,000 | -3.3% | 30,000 | 0.0% | 1.31% | +8.1% | |
| ENTX | Entera Bio Ltd | $1,184,000 | -19.7% | 475,540 | 0.0% | 1.08% | -10.2% | |
| CTVA | Corteva Inc | $840,000 | -5.3% | 30,000 | 0.0% | 0.77% | +5.9% | |
| MTEM | Molecular Templates | $751,000 | -21.0% | 113,905 | 0.0% | 0.69% | -11.8% | |
| SNGX | Sell | Soligenix Inc. | $748,000 | +25.7% | 787,830 | -6.0% | 0.68% | +40.7% |
| GLMD | Sell | Galmed Pharmaceuticals Ltd | $696,000 | -54.1% | 145,694 | -29.3% | 0.64% | -48.6% |
| CATS | Buy | Catasys Inc | $678,000 | +141.3% | 43,034 | +194.5% | 0.62% | +170.0% |
| ECOR | Sell | Electrocore Inc | $481,000 | -39.4% | 219,844 | -44.6% | 0.44% | -32.3% |
| LPCN | Lipocine Inc New | $141,000 | +45.4% | 50,000 | 0.0% | 0.13% | +63.3% | |
| VBLT | Vascular Biogenics Ltd | $29,000 | +3.6% | 21,400 | 0.0% | 0.03% | +17.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.